
    
      The drug being tested in this study is called Cabozantinib. Cabozantinib is being tested to
      treat people who have advanced renal cell carcinoma. This study will look at the efficacy of
      cabozantinib.

      The study will enroll approximately 35 patients. Participants will be enrolled in one
      treatment group in non-randomized and opened manner:

      â€¢ Cabozantinib 60 mg

      All participants will be asked to take tablets of cabozantinib at once daily in the fasted
      state throughout the study.

      This multi-center trial will be conducted in Japan. The overall time to participate in this
      study is approximately at most 3 years. Participants will make multiple visits to the clinic
      in treatment period, and posttreatment period including a follow-up assessment after last
      dose of study drug.
    
  